A First-in-Class ADC Platform
Targeting A Universal Tumor-Selective Dependency

A selective extracellular target with a “Trojan Horse” active-uptake mechanism — scaling across solid tumors through a single, unified mechanism.

Get in touch See the science ↓

Our Science

A structural target the tumor cannot hide.

Our lead antibody, CMX-102, recognizes a cryptic epitope called HU177 — a piece of collagen that stays folded away inside healthy tissue and is exposed when a tumor remodels the matrix around it. Once engaged, CMX-102 is actively taken up by tumor cells and the surrounding “bad actor” cells — CAFs (cancer-associated fibroblasts) and TAMs (tumor-associated macrophages) — that make solid tumors so hard to treat.

↔

Broad reach

The same target is present across many collagen-rich solid tumors, not confined to one indication.

◎

High selectivity

Essentially absent from healthy resting tissue, supporting a wide therapeutic window.

⟲

Built to last

A structural target rather than a surface receptor, so it isn't lost to the resistance mechanisms that erode many other ADCs.

PAYLOAD DELIVERY NO BYSTANDER RELIANCE

Present across: Ovarian Pancreatic Sarcoma Glioblastoma Mesothelioma and other fibrous, collagen-rich tumors

De-risked, not hypothetical

Built on a clinically tested antibody.

Most early-stage ADC programs carry no human data on the antibody itself. CryptoMedix's backbone antibody has already been in patients.

patients dosed in a U.S. Phase 1/2 safety study of the naked antibody

dose-limiting toxicities observed, at any dose level tested

24 mg/kg

highest dose reached, with early signs of anti-tumor activity

100%

tumor regression achieved in multiple pre-clinical ADC models

In vivo validation — complete regression in multiple models

In two independent ovarian carcinoma xenograft models, CMX-102-MMAE reversed established tumor growth to near-complete regression, while control-treated tumors continued to grow unchecked.

SKOV-3 Ovarian Carcinoma

Mean tumor volume over time

CMX-102-MMAE IgG-MMAE control

HeyA8 Ovarian Carcinoma

Mean tumor volume over time

CMX-102-MMAE IgG-MMAE control

N = 6–7 per arm · tumors seeded subcutaneously, dosing began at 150–200 mm³ · 5 mg/kg CMX-102-MMAE, intraperitoneal, 3× weekly · vs. IgG-MMAE isotype control.

Intellectual property. The program is protected by an issued and pending patent portfolio covering the antibody and the ADC composition across the United States, Europe, and Canada.

Leadership

A team that has built and sold biotechs before.

CryptoMedix is led by executives and scientists with a long record in oncology drug development and company-building.

Bernd R. Seizinger, MD, PhD

Co-founder & Chairman

Two prior biotech IPOs and $300M+ raised across public and private financings.

Sebastian Meier-Ewert, PhD

Designated CEO

Serial biotech founder and CEO; $300M+ raised across prior ventures.

Marcel Rozencweig, MD

Co-founder & Chief Medical Officer

More than a dozen oncology drug approvals; architect of the FDA accelerated-approval procedure.

Prof. Peter Brooks, PhD

Co-founder & Chief Science Advisor

Discoverer of the HU177 epitope and originating scientific authority on the platform.

Charlie Ault, MBA, CFP

Chief Financial Officer

30+ years of investment management experience; former bank officer.

Hemanshu Shah, PhD, MBA

Chief Business Officer

Broad oncology leadership across commercial, medical affairs, R&D and business development.

Scientific & Medical Advisory Board

Senior oncology, clinical, and matrix-biology expertise supporting the leadership team

Prof. Alexander Eggermont, MD, PhDSenior Medical Oncology & Science Advisor

Jean-Pierre Bizzari, MDSenior Medical Oncology Advisor

Robert Miller, FRCS, MBBS, FFPMSenior Medical Oncology Advisor

Sarah Arbe-Barnes, PhD, MFPMSenior Medical Oncology Advisor

Lars Stahl-Wegner, MDSenior Strategic Advisor

Anthony Montgomery, PhDSenior Science Advisor & Co-founder

Calvin Vary, PhDSenior Science Advisor & Co-founder

Interested in learning more?

We're engaging with investors and partners who share our interest in reaching the solid tumors other approaches leave behind.

info@cryptomedix.com

A First-in-Class ADC PlatformTargeting A Universal Tumor-Selective Dependency